Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroimaging in multiple sclerosis

D H Miller1, W I McDonald

  • 1Institute of Neurology, London, United Kingdom.

Clinical Neuroscience (New York, N.Y.)
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measurements of the exclusive decays of the upsilon(5S) to meson final states and improved B(s)* mass measurement.

Physical review letters·2006
Same author

Charmonium Decays of Y(4260), psi(4160), and psi(4040).

Physical review letters·2006
Same author

Observation of Psi(3770)-->gammachi(c1)-->gammagammaJ/Psi.

Physical review letters·2006
Same author

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

Neurology·2006
Same author

Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis.

Brain : a journal of neurology·2006
Same author

Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis.

Journal of neurology·2006
Same journal

Cardiovascular autonomic dysfunction in parkinsonian patients.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Visuo-cognitive dysfunctions in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Gastrointestinal dysfunction in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Respiratory function in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Neurophysiology of sensorimotor integration in Parkinson's disease.

Clinical neuroscience (New York, N.Y.)·2000
Same journal

Imaging of nonmotor symptoms in Parkinson syndromes.

Clinical neuroscience (New York, N.Y.)·2000
See all related articles

Magnetic resonance imaging (MRI) is crucial for diagnosing multiple sclerosis (MS) and evaluating spinal cord conditions. Advanced MRI techniques offer insights into MS relapses, remission, and disability progression.

Area of Science:

  • Neuroimaging
  • Neurology
  • Radiology

Background:

  • Magnetic resonance imaging (MRI) significantly aids in assessing patients with multiple sclerosis (MS).
  • Brain MRI is a primary diagnostic tool for MS.
  • Advancements in spinal cord imaging enhance MRI's utility for myelopathies and suspected MS with unclear brain findings.

Purpose of the Study:

  • To highlight the diagnostic and mechanistic contributions of MRI in multiple sclerosis.
  • To discuss the role of MRI in evaluating spinal cord disorders.
  • To explore MRI markers for understanding MS relapse, remission, and disability.

Main Methods:

  • Utilizing magnetic resonance imaging (MRI) for brain and spinal cord assessment.
  • Employing MRI to identify putative markers of inflammation and axonal loss.

Related Experiment Videos

  • Applying monthly MRI for screening new therapies in relapsing forms of MS.

    • Main Results:

    • Brain MRI is the most valuable diagnostic investigation for MS.
    • Spinal cord MRI is effective for evaluating undiagnosed myelopathies and probable MS with equivocal brain imaging.
    • MRI markers provide insights into MS relapse/remission mechanisms and persistent disability.

    Conclusions:

    • MRI is indispensable in the comprehensive evaluation and management of multiple sclerosis.
    • While valuable for therapy screening, definitive clinical endpoints remain essential for long-term disability assessment in MS trials.